Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from D. Boral Capital
Quince Therapeutics (NASDAQ:QNCX – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $4.00 target price on the stock. D. Boral Capital’s price target would suggest a potential upside of 236.13% from the company’s current price. A […]
Quince Therapeutics (NASDAQ:QNCX – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $4.00 target price on the stock. D. Boral Capital’s price target would suggest a potential upside of 236.13% from the company’s current price. A […]
